Outset Medical (OM) Stock
Dialysis system maker simplifying care for hospitals and homes. Here's the price, business snapshot, and what's worth knowing about Outset Medical in October 2026.
Outset Medical (OM) designs and manufactures haemodialysis systems intended for hospital, clinic and home settings. The company is best known for the Tablo system, which targets simplification of dialysis delivery and operational efficiency. As a small-cap medical-device business (market capitalisation provided at around $271m), Outset sits in a competitive, highly regulated healthcare segment where growth depends on clinical adoption, reimbursement policies and hospital procurement cycles. Potential upside comes from rising demand for dialysis services globally and any gains in market share for easier-to-use or lower-cost systems. Key risks include regulatory review, reimbursement pressures, execution on manufacturing and commercial scale-up, and the typical volatility of smaller, growth-oriented healthcare firms. This profile is educational and not investment advice — investors should review the company’s latest regulatory filings, recent results and consult a financial professional to assess suitability given that share values can fall as well as rise.
Outset Medical (OM) Stock Forecast
Analyst price target, next 12 months
$6.25
+42.4% vs today's $4.39
Price range over the last 12 months
Close to its 12-month low
Analysts covering Outset Medical have a consensus 12-month target of $6.25, above the current price of $4.39.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Outset Medical's stock, anticipating potential growth in value.
Financial Health
Outset Medical Inc is showing strong revenue and cash flow, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption Opportunity
The Tablo system aims to simplify dialysis delivery, which could support commercial adoption — though uptake depends on clinical acceptance and procurement cycles.
Global Demand Trends
Ageing populations and rising chronic kidney disease suggest structural demand for dialysis, yet reimbursement and regional regulation can strongly influence outcomes.
Execution Risks
Scaling manufacturing, navigating approvals and competing with larger players are key execution challenges; small-cap stocks can be particularly volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
